|
|
|
|
Teva Pharmaceutical Industries Limited - Pharmaceuticals & Healthcare - Deals and Alliances Profile - new
www.companiesandmarkets.com/Summary-Company-Profile/teva-pharmac ..Teva Pharmaceutical Industries Limited - Pharmaceuticals & Healthcare - Deals and Alliances Profile is an essential source for company data and information. The profile examines the...
|
|
|
News and FDA Updates for OPTIMIZERx (OTC:OPRX), Teva (Nasdaq:TEVA) , S3 (OTC:SIVC)
BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials...
|
|
|
Teva Settles Patent Litigation with Novartis
Teva Pharmaceutical Industries has announced that its subsidiary, Teva Pharmaceuticals USA, Inc., has signed an agreement with Novartis to settle patent litigation involving Teva's U.S.generic version of Novartis' Famvir (famciclovir) 125 mg, 250 mg...
|
|
|
Teva and Novartis reach settlement on Famvir suit
Pharmaceuticals Teva Pharmaceutical Industries Ltd Novartis AG Story Quotes Comments Screener AlertEmail Print By Sue Chang TEVANVS SAN FRANCISCO (MarketWatch) -- Teva Pharmaceutical Industries Ltd./quotes/comstock/15*!teva/quotes/nls/teva (TEVA 57.94, -0.20...
|
|
|
News and FDA Updates for OPTIMIZERx (OTC:OPRX), Teva (Nasdaq:TEVA) , S3 (OTC:SIVC)
BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials and...
|
|
|
News and FDA Updates for OPTIMIZERx (OTC:OPRX), Teva (Nasdaq:TEVA) , S3 (OTC:SIVC)
BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials...
|
|
|
News and FDA Updates for OPTIMIZERx (OTC:OPRX), Teva (Nasdaq:TEVA) , S3 (OTC:SIVC)
BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials...
|
|
|
Teva settles patent lawsuit with Novartis
(Datamonitor via COMTEX) -- Teva Pharmaceutical Industries has reported that its subsidiary, Teva Pharmaceuticals USA, has signed an agreement with Novartis to settle patent litigation involving Teva's US generic version of Novartis's Famvir 125mg, 250mg...
|
|
|
Teva settles patent lawsuit with Novartis - Zibb.com
Companies: Novartis AG (NVS), Teva Pharmaceutical Industries, Ltd (TEVA) Teva Pharmaceutical Industries has reported that its subsidiary, Teva Pharmaceuticals USA, has signed an agreement with Novartis to settle patent litigation involving Teva's US generic...
|
|
|
News and FDA Updates for Teva (Nasdaq:TEVA), Vitro Diagnostics (OTC:VODG), XenaCare (OTC:XCHO)
BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials...
|
|
|
BiomedReports: News and FDA Updates for Teva (Nasdaq:TEVA), Vitro...
Companies: Teva Pharmaceutical Industries, Ltd (TEVA), XenaCare Holdings Inc (XCHO) BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors...
|
|
|
Teva settles patent lawsuit with Novartis
Teva Pharmaceutical Industries has reported that its subsidiary, Teva Pharmaceuticals USA, has signed an agreement with Novartis to settle patent litigation involving Teva's US generic version of Novartis's Famvir 125mg, 250mg and 500mg tab Teva settles...
|
|
|
Teva settles patent lawsuit with Novartis
Teva Pharmaceutical Industries has reported that its subsidiary, Teva Pharmaceuticals USA, has signed an agreement with Novartis to settle patent litigation involving Teva's US generic version of Novartis's Famvir 125mg, 250mg and 500mg tab Teva settles...
|
|
|
BiomedReports: News and FDA Updates for Teva (Nasdaq:TEVA), Vitro Diagnostics (OTC:VODG), XenaCare (OTC:XCHO)
BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials...
|
|
|
Teva Just Misses, But Revenues Rise
Teva Pharmaceutical Industries (TEVA) fourth quarter earnings of 94 cents per American Depository Share (ADS) missed the Zacks Consensus Estimate by a cent.Earnings, however, increased 18% from the year-ago period. Annual earnings were in line with the...
|
|
|
News and FDA Updates for Teva (Nasdaq:TEVA), Vitro Diagnostics (OTC:VODG), XenaCare (OTC:XCHO)
BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials...
|
|
|
News and FDA Updates for Teva (Nasdaq:TEVA), Vitro Diagnostics (OTC:VODG), XenaCare (OTC:XCHO)
BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials...
|
|
|
Teva predicts 15 percent revenue growth in 2010 to $16b: The company reiterates profit guidance of $4.40-4.60
Teva Pharmaceutical Industries Ltd.( NASDAQ:TEVA; TASE: TEVA) reiterated its profit guidance of $4.40-4.60 per share in 2010 in the conference call following the publication of its financial report for the fourth quarter and full year of 2009. Teva also...
|
|
|
Teva predicts 15 percent revenue growth in 2010 to $16b: The company reiterates profit guidance of $4.40-4.60 per share for the
(Globes - McClatchy-Tribune Information Services via COMTEX) -- Teva Pharmaceutical Industries Ltd.(Nasdaq: TEVA; TASE: TEVA | Quote | Chart | News | PowerRating) reiterated its profit guidance of $4.40-4.60 per share in 2010 in the conference call following...
|
|
|
Teva, Novartis Settle Suit Over Generic Famvir
Israel-based Teva Pharmaceutical Industries Ltd.has announced that its U.S. unit has settled a patent infringement suit brought by Novartis AG over a generic version of genital herpes drug Famvir. Teva, Novartis Settle Suit Over Generic Famvir....
|
|
|
Teva Pharmaceutical Industries settles Famvir lawsuit with Novartis for undisclosed amount
NEW YORK Teva Pharmaceutical said its U.S.unit has settled a patent dispute over a herpes treatment made by Novartis. Teva launched a generic version of the drug Famvir in 2007. Under the agreement announced Monday, Teva will make a one-time...
|
|
|
Teva Pharmaceutical settles lawsuit with Novartis
NEW YORK (AP) -- Teva Pharmaceutical said its U.S.unit has settled a patent dispute over a herpes treatment made by Novartis.Teva launched a generic version of the drug Famvir in 2007.Under the agreement announced Monday, Teva will make a one-time...
|
|
|
Teva Announces Agreement on Famvir Patent Challenge
JERUSALEM(BUSINESS WIRE) Teva Pharmaceutical Industries Ltd.(Nasdaq: TEVA) today announced that its subsidiary, Teva Pharmaceuticals USA, Inc., has signed an agreement with Novartis to settle patent litigation involving Teva's U.S. generic version of...
|
|
|
Teva Announces Agreement on Famvir Patent Challenge
- Teva Pharmaceutical Industries Ltd.(Nasdaq: TEVA) today announced that its subsidiary, Teva Pharmaceuticals USA, Inc., has signed an agreement with Novartis to settle patent litigation involving Teva's U.S. generic version of Novartis' Famvir ...
|
|
|
Teva Pharmaceutical Settles Lawsuit with Novartis
NEW YORK -- Teva Pharmaceutical said its U.S.unit has settled a patent dispute over a herpes treatment made by Novartis. Teva launched a generic version of the drug Famvir in 2007. Under the agreement announced Monday, Teva will make a one-time...
|
